Dublin, Oct. 15, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/zqgsfs/global_hemophilia) has announced the addition of the "Global Hemophilia B Market 2015-2019 - Industry Analysis" report to their offering.

The global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Major vendors are entering into strategic alliances for drug development. Strategic alliances, in terms of licensing and collaboration, help vendors co-develop and commercialize drugs in different regions.

According to the report, prophylactic treatment is fast gaining popularity among physicians and patients. The treatment increases patients' quality of life in terms of physical strength. It also maintains optimum levels of clotting factors, prevent spontaneous bleeding in individuals with hemophilia B, and reduce joint damage and pains.

Further, the report states that the high cost of treatment leads to the discontinuation of therapy by patients, thereby hampering market growth.

Key vendors

• Baxter
• Grifols
• Novo Nordisk
• Pfizer

Other prominent vendors

• Alnylam
• Amarna
• Asklepios
• Biogen
• Catalyst Biosciences
• CSL Behring
• Dimension Therapeutics
• Dong-A Scio
• Emergent BioSolutions

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Disease overview

Part 07: Pipeline portfolio

Part 08: Market segmentation by disease severity

Part 09: Market segmentation by disease management

Part 10: Geographical segmentation

Part 11: Market drivers

Part 12: Impact of drivers

Part 13: Market challenges

Part 14: Impact of drivers and challenges

Part 15: Market trends

Part 16: Vendor landscape

Part 17: Key vendor analysis

For more information visit http://www.researchandmarkets.com/research/zqgsfs/global_hemophilia

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716

         Sector: Healthcare and Medical Devices

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.